Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:


Last Updated: January 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Pictilisib

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Pictilisib?

Pictilisib is an investigational drug.

There have been 4 clinical trials for Pictilisib. The most recent clinical trial was a Phase 1 trial, which was initiated on March 1st 2013.

The most common disease conditions in clinical trials are Breast Neoplasms, Gliosarcoma, and Glioblastoma. The leading clinical trial sponsors are Genentech, Inc., Department of Experimental Clinical Oncology, Aarhus University Hospital, and Royal Marsden NHS Foundation Trust.

There are one hundred and five US patents protecting this investigational drug and nine hundred and seventy-one international patents.

Recent Clinical Trials for Pictilisib
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibInstitute of Cancer Research, United KingdomPhase 1
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibPfizerPhase 1
PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclibRoche Pharma AGPhase 1

See all Pictilisib clinical trials

Clinical Trial Summary for Pictilisib

Top disease conditions for Pictilisib
Top clinical trial sponsors for Pictilisib

See all Pictilisib clinical trials

US Patents for Pictilisib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pictilisib   Start Trial In vitro production of foregut stem cells Cambridge Enterprise Limited (GB)   Start Trial
Pictilisib   Start Trial Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines Signal Pharmaceuticals, LLC (San Diego, CA)   Start Trial
Pictilisib   Start Trial Methods of treating PR-positive, luminal A breast cancer with PI3K inhibitor, pictilisib Genentech, Inc. (South San Francisco, CA)   Start Trial
Pictilisib   Start Trial Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activity The University of North Carolina at Chapel Hill (Chapel Hill, NC)   Start Trial
Pictilisib   Start Trial Antibody drug conjugates Novartis AG (Basel, CH)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pictilisib

Drugname Country Document Number Estimated Expiration Related US Patent
Pictilisib Australia 2014333942 2033-10-09   Start Trial
Pictilisib Canada 2963886 2033-10-09   Start Trial
Pictilisib China 105793414 2033-10-09   Start Trial
Pictilisib European Patent Office 3060652 2033-10-09   Start Trial
Pictilisib United Kingdom 201317869 2033-10-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.